Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!

Related Content

Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First

ByJayaprakash Nair

December 3rd 2025

Medical banner Pulmonary fibrosis on blue background | Image Credit: © mi_viri -stock.adobe.com

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

BySusan Haigney

December 2nd 2025

Hand holding a stylus over a tablet with futuristic risk management icons such as warning signs, data charts, and safety symbols on a dark background. | Image Credit: ©ImageFlow -stock.adobe.com

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

BySusan Haigney

December 2nd 2025

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Deploys Agentic AI Capabilities for Agency Staff

BySusan Haigney

December 2nd 2025

Fluorescent Imaging immunofluorescence of cancer cells growing in 2D with nuclei in blue, cytoplasm in red and DNA damage foci in green | Image Credit: ©drimafilm - stock.adobe.com

Live Cell High-Content Imaging Is Driving Drug Discovery

ByCheryl Barton

December 1st 2025

E-Procurement  Reverse Auctions and the Supplier's Perspective

Articles in this issue

Newsletter

Related Content

Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

FDA Deploys Agentic AI Capabilities for Agency Staff

Live Cell High-Content Imaging Is Driving Drug Discovery

Trending on Pharmaceutical Technology

Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment

FDA Deploys Agentic AI Capabilities for Agency Staff

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

E-Procurement &#151; Reverse Auctions and the Supplier's Perspective

Articles in this issue

Newsletter

Related Content

Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

FDA Deploys Agentic AI Capabilities for Agency Staff

Live Cell High-Content Imaging Is Driving Drug Discovery

Trending on Pharmaceutical Technology

Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment

FDA Deploys Agentic AI Capabilities for Agency Staff

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

E-Procurement Reverse Auctions and the Supplier's Perspective